Integra Lifesciences Holdings Corp (NASDAQ:IART) VP Joseph Vinhais sold 6,800 shares of the company’s stock in a transaction dated Friday, March 9th. The shares were sold at an average price of $54.13, for a total transaction of $368,084.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Shares of Integra Lifesciences Holdings Corp (NASDAQ IART) opened at $56.23 on Wednesday. The firm has a market cap of $4,305.41, a P/E ratio of 68.57, a P/E/G ratio of 1.69 and a beta of 0.65. The company has a debt-to-equity ratio of 1.85, a current ratio of 2.36 and a quick ratio of 1.51. Integra Lifesciences Holdings Corp has a 52-week low of $40.51 and a 52-week high of $56.42.
Integra Lifesciences (NASDAQ:IART) last announced its quarterly earnings results on Tuesday, February 27th. The life sciences company reported $0.64 earnings per share for the quarter, beating analysts’ consensus estimates of $0.56 by $0.08. The business had revenue of $368.60 million for the quarter, compared to the consensus estimate of $362.64 million. Integra Lifesciences had a net margin of 5.45% and a return on equity of 16.94%. Integra Lifesciences’s revenue for the quarter was up 44.2% on a year-over-year basis. During the same period last year, the company posted $0.52 EPS. research analysts predict that Integra Lifesciences Holdings Corp will post 2.33 earnings per share for the current fiscal year.
Hedge funds have recently made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Integra Lifesciences by 38.3% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,806 shares of the life sciences company’s stock worth $182,000 after buying an additional 1,054 shares during the period. Zions Bancorporation acquired a new stake in Integra Lifesciences during the 3rd quarter worth approximately $205,000. Xact Kapitalforvaltning AB acquired a new stake in Integra Lifesciences during the 4th quarter worth approximately $311,000. Campbell Newman Asset Management Inc. raised its holdings in Integra Lifesciences by 21.5% during the 4th quarter. Campbell Newman Asset Management Inc. now owns 6,964 shares of the life sciences company’s stock worth $333,000 after buying an additional 1,234 shares during the period. Finally, Oppenheimer & Co. Inc. raised its holdings in Integra Lifesciences by 25.2% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 7,293 shares of the life sciences company’s stock worth $368,000 after buying an additional 1,466 shares during the period. Hedge funds and other institutional investors own 90.93% of the company’s stock.
WARNING: This article was published by Markets Daily and is the property of of Markets Daily. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.themarketsdaily.com/2018/03/14/integra-lifesciences-holdings-corp-iart-vp-joseph-vinhais-sells-6800-shares.html.
About Integra Lifesciences
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.